Evaluating Preference Trials of Oral Phosphodiesterase 5 Inhibitors for Erectile Dysfunction
- 31 January 2006
- journal article
- review article
- Published by Elsevier BV in European Urology
- Vol. 49 (1), 30-37
- https://doi.org/10.1016/j.eururo.2005.09.001
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Understanding erectile dysfunction medication preference studiesCurrent Opinion in Urology, 2004
- Rechallenge prior sildenafil nonrespondersInternational Journal of Impotence Research, 2004
- Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: Results of a European multicenter, open-label study of patient preferenceClinical Therapeutics, 2003
- Deciphering Erectile Dysfunction Drug TrialsJournal of Urology, 2003
- Achieving treatment optimization with sildenafil citrate (Viagra®) in patients with erectile dysfunctionUrology, 2002
- Combination therapy for erectile dysfunction: a randomized, double blind, unblinded active-controlled, cross-over study of the pharmacodynamics and safety of combined oral formulations of apomorphine hydrochloride, phentolamine mesylate and papaverine hydrochloride in men with moderate to severe erectile dysfunctionInternational Journal of Impotence Research, 2002
- The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and ElaborationAnnals of Internal Medicine, 2001
- CONSORT: An Evolving Tool to Help Improve the Quality of Reports of Randomized Controlled TrialsJAMA, 1998
- Clinical Trials in Chronic DiseasesThe Journal of Clinical Pharmacology, 1995
- Empirical Evidence of BiasJAMA, 1995